GlassScriptPhysician profile
Vicki Chapman
NPI 1356764468
$56,737.70
in general payments reported to CMS, 2019-2025
30 companies · $6,724 in 2025
The $6,724 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21K · 2022: $9,334 · 2023: $13K · 2024: $6,612 · 2025: $6,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,625 · Food and Beverage: $6,743 · Travel and Lodging: $5,489 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,050 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,150 · Honoraria: $175 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,625.00 |
| Food and Beverage | $6,742.65 |
| Travel and Lodging | $5,489.15 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,050.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,150.00 |
| Honoraria | $175.00 |
| Education | $107.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $35,261.89 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbott Laboratories | $7,191.11 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $4,902.07 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $3,023.91 | 2021-2025 | Minimed 780g, Minimed 770g |
| Mannkind Corporation | $1,685.61 | 2023-2025 | Afrezza |
| Lilly USA, LLC | $870.17 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $572.25 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Rgh Enterprises LLC | $540.00 | 2022 | |
| Senseonics, Incorporated | $400.00 | 2025 | Eversense |
| Cequr Corporation | $380.91 | 2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.64 | 2021-2025 | Jardiance |
| Corcept Therapeutics | $301.27 | 2021-2025 | Korlym |
| Insulet Corporation | $295.25 | 2021-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $244.42 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.79 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $90.57 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Recordati_rare_diseases_inc. | $84.25 | 2025 | Isturisa |
| Tandem Diabetes Care, INC. | $76.73 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $67.24 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $61.54 | 2021-2022 | |
| Boston Scientific Corporation | $37.05 | 2024 | Bodyguardian |
| Abbvie INC. | $35.99 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $33.24 | 2021 | |
| Glaxosmithkline, LLC. | $31.54 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Catalyst Pharmaceuticals, INC. | $24.67 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $19.44 | 2025 | |
| Zealand Pharma US, INC. | $19.33 | 2021 | |
| Ascendis Pharma Endocrinology INC | $18.99 | 2025 | Yorvipath |
| Currax Pharmaceuticals LLC | $16.15 | 2025 | Contrave |
| Astellas Pharma US INC | $14.68 | 2021-2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.